Results 111 to 120 of about 7,833 (210)
Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia
BMC Infectious DiseasesBackground X-linked agammaglobulinemia (XLA), also referred to as Bruton’s tyrosine kinase deficiency, is a rare genetic disorder that affects the immune system.
Bowen Dai +15 more
doaj +1 more source
HemaSphere, Volume 10, Issue 6, June 2026.Abstract IGLV3‐21R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors.
Deyan Y. Yosifov +24 more
wiley +1 more source
HemaSphere, Volume 10, Issue 6, June 2026.Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada +17 more
wiley +1 more source
A structure‐activity investigation of the fungal metabolite (‐)‐TAN‐2483B: inhibition of Bruton’s tyrosine kinase [PDF]
The natural product (‐)‐TAN‐2483B is a fungal secondary metabolite which displays promising anti‐cancer and immunomodulatory activity. Our previous syntheses of (‐)‐TAN‐2483B and sidechain analogues uncovered inhibitory activity against Bruton’s tyrosine
Flanagan, Jack U. +3 more
core +1 more source
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Kinases and PhosphatasesBruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj +1 more source
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation
HemaSphere, Volume 10, Issue 6, June 2026.Abstract Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL.
Barbara Eichhorst +13 more
wiley +1 more source
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
Bruton’s tyrosine kinase (BTK) is a Tec family kinase that plays an essential role in B-cell receptor (BCR) signaling as well as Fcγ receptor signaling in leukocytes.
Mark S. Tichenor (2468158) +33 more
core +2 more sources
American Journal of Hematology, Volume 101, Issue 7, Page 1516-1521, July 2026.
Jennifer A. Woyach +16 more
wiley +1 more source
Treatment Outcomes and Overall Survival of Patients With B‐Cell Prolymphocytic Leukemia
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction B‐cell prolymphocytic leukemia (B‐PLL) is a rare, aggressive leukemic B‐cell malignancy historically associated with poor outcomes and recently reclassified in the WHO Fifth Edition but retained as a distinct entity in the ICC.
Daniel A. Ermann +6 more
wiley +1 more source
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Background Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase inhibition (BTKi) and chimeric antigen receptor T‐cell (CAR‐T) therapy.
Enver Aydilek +6 more
wiley +1 more source